Mr. Junk’s practice consists chiefly of the defense of corporate clients in complex serial and mass tort litigation, including both state and federal court multi-district litigation proceedings. In this role, Mr. Junk typically works first to devise and then to implement a defense to hundreds – if not thousands – of cases pending in forums nationwide. Consequently, Mr. Junk has a broad range of litigation experience in venues across the country.

Throughout his career, Mr. Junk has defended a Firm client against hundreds of personal injury lawsuits involving prescription pharmaceuticals (ergot alkaloids) and claims of cardiovascular and cerebrovascular injuries. He has worked on the national defense of personal injury litigation involving thousands of plaintiffs’ allegations of neurological injury - including Parkinson’s disease, ALS, and other Parkinson’s-like disorders - claimed to be the result of exposure to welding fumes. And Mr. Junk was part of the defense team representing a major medical device manufacturer against numerous personal injury, class-action, and medical-monitoring claims that followed the voluntary recall of an innovative surgical mesh.

Given this background, Mr. Junk has extensive experience in pretrial discovery (including corporate witness preparation), motions practice, mediation, and settlement. In addition to this more traditional litigation experience, Mr. Junk also has developed and conducted innovative jury research projects for some of the Firm’s largest clients.

Through a number of publications, Mr. Junk has commented on certain developments in the law. With Firm partner Bruce Berger, Mr. Junk has written about the emerging tort liability aspects of "endocrine disrupters." And with Firm partner Eric Lasker, Mr. Junk has written about the product liability implications of the pleading standard described by the Supreme Court in two seminal decisions, Ashcroft v. Iqbal and Bell Atlantic Corporation v. Twombly.